Yuanzhi Xia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuanzhi Xia has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Cailing Wan
Department of Clinical Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, People’s Republic of China
1 shared publication- Caitlin M. Gillis
Unit of Antibodies in Therapy and Pathology, Institut Pasteur, UMR1222 INSERMF-75015, Paris, France
1 shared publication - Fangyou Yu
Department of Clinical Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China
1 shared publication Haojin Gao
Department of Clinical Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, People’s Republic of China
1 shared publication- James Anthony Triccas
Sydney Infectious Diseases Institute (Sydney ID), Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia
1 shared publication Jiawei Ding
Department of Medical Laboratory, The Affiliated Yan’an Hospital of Kunming Medical University, Kunming, Yunnan, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 1 November 2025
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 18, 6153-6165
Genomic and Phenotypic Characterization of Extensively Drug-Resistant Clinical Klebsiella quasipneumoniae subsp. similipneumoniae ST1929 Isolates
Background: Klebsiella quasipneumoniae subsp. similipneumoniae is an emerging member of the K. pneumoniae complex that is often misidentified in routine diagnostics. Its clinical relevance and genomic characteristics remain poorly understood. Methods: Four K. quasipneumoniae subsp. similipneumoniae isolates were collected from hospitalized patients in different wards and identified by whole-genome sequencing. Antimicrobial susceptibility testing was conducted using the broth microdilution method. Phylogenetic, comparative genomic, and plasmid transfer analyses were conducted to elucidate genetic relatedness and resistance mobility. Virulence phenotypes were assessed by measuring capsule production, biofilm formation, serum resistance, and in vivo pathogenicity in a Galleria mellonella infection model. Results: All four isolates belonged to the novel ST1929-KL159 clonotype and exhibited an extensively drug-resistant phenotype, with resistance to β-lactams, carbapenems, fluoroquinolones, tigecycline, and trimethoprim-sulfamethoxazole. Amikacin was the only consistently active agent; one isolate showed high-level resistance to polymyxin B due to a premature stop mutation in mgrB (Gln30*). Genomic analysis revealed the coexistence of blaNDM-1 and the tigecycline resistance cluster tmexC2D2-toprJ2 on a IncU plasmid, which transferred efficiently to E. coli recipients. Comparative genomics demonstrated strong similarity to multidrug-resistant plasmids from diverse Enterobacterales. Phylogenetic analysis confirmed the global distribution of K. quasipneumoniae subsp. similipneumoniae but highlighted the rarity of ST1929, with close relatedness among the four isolates suggesting recent nosocomial transmission. Despite the absence of classical virulence genes, ST1929 exhibited enhanced biofilm formation, moderate capsule production, and intermediate serum resistance, but low virulence in the G. mellonella model. Conclusion: This study provides the first description of K. quasipneumoniae subsp. similipneumoniae ST1929, an extensively drug-resistant lineage harboring blaNDM-1 and the tigecycline resistance cluster tmexC2D2-toprJ2 on a transferable IncU plasmid. The findings underscore the need for accurate detection and surveillance of this rare lineage.
- 1 November 2025
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 18, 6153-6165
Open AccessGenomic and Phenotypic Characterization of Extensively Drug-Resistant Clinical Klebsiella quasipneumoniae subsp. similipneumoniae ST1929 Isolates
Background: Klebsiella quasipneumoniae subsp. similipneumoniae is an emerging member of the K. pneumoniae complex that is often misidentified in routine diagnostics. Its clinical relevance and genomic characteristics remain poorly understood. Methods: Four K. quasipneumoniae subsp. similipneumoniae isolates were collected from hospitalized patients in different wards and identified by whole-genome sequencing. Antimicrobial susceptibility testing was conducted using the broth microdilution method. Phylogenetic, comparative genomic, and plasmid transfer analyses were conducted to elucidate genetic relatedness and resistance mobility. Virulence phenotypes were assessed by measuring capsule production, biofilm formation, serum resistance, and in vivo pathogenicity in a Galleria mellonella infection model. Results: All four isolates belonged to the novel ST1929-KL159 clonotype and exhibited an extensively drug-resistant phenotype, with resistance to β-lactams, carbapenems, fluoroquinolones, tigecycline, and trimethoprim-sulfamethoxazole. Amikacin was the only consistently active agent; one isolate showed high-level resistance to polymyxin B due to a premature stop mutation in mgrB (Gln30*). Genomic analysis revealed the coexistence of blaNDM-1 and the tigecycline resistance cluster tmexC2D2-toprJ2 on a IncU plasmid, which transferred efficiently to E. coli recipients. Comparative genomics demonstrated strong similarity to multidrug-resistant plasmids from diverse Enterobacterales. Phylogenetic analysis confirmed the global distribution of K. quasipneumoniae subsp. similipneumoniae but highlighted the rarity of ST1929, with close relatedness among the four isolates suggesting recent nosocomial transmission. Despite the absence of classical virulence genes, ST1929 exhibited enhanced biofilm formation, moderate capsule production, and intermediate serum resistance, but low virulence in the G. mellonella model. Conclusion: This study provides the first description of K. quasipneumoniae subsp. similipneumoniae ST1929, an extensively drug-resistant lineage harboring blaNDM-1 and the tigecycline resistance cluster tmexC2D2-toprJ2 on a transferable IncU plasmid. The findings underscore the need for accurate detection and surveillance of this rare lineage.
- Open Access
- 1 July 2025
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 18, 3329-3341
Co-Production of KPC-2 and NDM-5 in a Carbapenem-Resistant Klebsiella Pneumoniae Clinical Isolate: Genetic Insights and Risks
Background: Carbapenem-resistant Klebsiella pneumoniae (CRKP), particularly strains co-producing KPC and NDM carbapenemases, poses a severe global health threat due to limited treatment options. Understanding the genetic drivers of resistance and transmission is critical. Methods: A multidrug-resistant CRKP strain, KP3T58, co-harboring blaKPC-2 and blaNDM-5, was isolated from an ICU patient. Whole-genome sequencing and comparative genomic analyses were performed. Plasmid transferability was assessed via conjugation assays using E. coli EC600 as the recipient. Virulence phenotypes were evaluated through siderophore production (CAS assay), capsule quantification (uronic acid), serum resistance, and Galleria mellonella infection models. Antimicrobial susceptibility was determined (Vitek-2; CLSI/EUCAST standards). Results: KP3T58 exhibited resistance to nearly all antibiotics except polymyxin. The strain’s multidrug-resistant (MDR) phenotype resulted from a combination of chromosomal mutations and the multiple plasmid-borne resistance genes. Whole-genome analysis identified three key plasmids: a conjugative plasmid pKP3T58_1 (IncFIB/FII/R type, carrying a large resistance gene cluster); a conjugative plasmid pKP3T58_2 (IncI1-I type, high-frequency transfer, carrying blaNDM-5); and a non-conjugative plasmid pKP3T58_3 (IncFII type, carrying blaKPC-2). Conjugation assays confirmed that pKP3T58_1 and pKP3T58_2 could transfer individually or jointly to E. coli EC600, while pKP3T58_3 (retaining only a partial T4SS) could co-transfer to recipient cells with the assistance of pKP3T58_2. MLST confirmed clonal persistence of the high-risk ST11 lineage within the patient. Phylogenetic analysis revealed KP3T58’s clustering within a dominant epidemic ST11-KL64 subclade prevalent in China. Multiple virulence assays (including siderophore production, capsule quantification, serum resistance, and Galleria mellonella infection models) demonstrated that KP3T58 lacks a typical hypervirulent phenotype but retains a certain level of pathogenicity. Conclusion: This study demonstrates clonal evolution of ST11 CRKP to co-produce KPC-2 and NDM-5 within a host, clustering within a prevalent epidemic lineage. Critically, we provide experimental evidence that mobilizable plasmids retaining only a partial T4SS can undergo horizontal transfer when assisted by conjugative plasmids, fundamentally expanding our understanding of resistance dissemination. The convergence of high-risk epidemiology, MDR, and novel plasmid transfer mechanisms in strains like KP3T58 necessitates enhanced surveillance and urgent molecular investigation into the transmission dynamics of these threats.
- 1 July 2025
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 18, 3329-3341
Open AccessCo-Production of KPC-2 and NDM-5 in a Carbapenem-Resistant Klebsiella Pneumoniae Clinical Isolate: Genetic Insights and Risks
Background: Carbapenem-resistant Klebsiella pneumoniae (CRKP), particularly strains co-producing KPC and NDM carbapenemases, poses a severe global health threat due to limited treatment options. Understanding the genetic drivers of resistance and transmission is critical. Methods: A multidrug-resistant CRKP strain, KP3T58, co-harboring blaKPC-2 and blaNDM-5, was isolated from an ICU patient. Whole-genome sequencing and comparative genomic analyses were performed. Plasmid transferability was assessed via conjugation assays using E. coli EC600 as the recipient. Virulence phenotypes were evaluated through siderophore production (CAS assay), capsule quantification (uronic acid), serum resistance, and Galleria mellonella infection models. Antimicrobial susceptibility was determined (Vitek-2; CLSI/EUCAST standards). Results: KP3T58 exhibited resistance to nearly all antibiotics except polymyxin. The strain’s multidrug-resistant (MDR) phenotype resulted from a combination of chromosomal mutations and the multiple plasmid-borne resistance genes. Whole-genome analysis identified three key plasmids: a conjugative plasmid pKP3T58_1 (IncFIB/FII/R type, carrying a large resistance gene cluster); a conjugative plasmid pKP3T58_2 (IncI1-I type, high-frequency transfer, carrying blaNDM-5); and a non-conjugative plasmid pKP3T58_3 (IncFII type, carrying blaKPC-2). Conjugation assays confirmed that pKP3T58_1 and pKP3T58_2 could transfer individually or jointly to E. coli EC600, while pKP3T58_3 (retaining only a partial T4SS) could co-transfer to recipient cells with the assistance of pKP3T58_2. MLST confirmed clonal persistence of the high-risk ST11 lineage within the patient. Phylogenetic analysis revealed KP3T58’s clustering within a dominant epidemic ST11-KL64 subclade prevalent in China. Multiple virulence assays (including siderophore production, capsule quantification, serum resistance, and Galleria mellonella infection models) demonstrated that KP3T58 lacks a typical hypervirulent phenotype but retains a certain level of pathogenicity. Conclusion: This study demonstrates clonal evolution of ST11 CRKP to co-produce KPC-2 and NDM-5 within a host, clustering within a prevalent epidemic lineage. Critically, we provide experimental evidence that mobilizable plasmids retaining only a partial T4SS can undergo horizontal transfer when assisted by conjugative plasmids, fundamentally expanding our understanding of resistance dissemination. The convergence of high-risk epidemiology, MDR, and novel plasmid transfer mechanisms in strains like KP3T58 necessitates enhanced surveillance and urgent molecular investigation into the transmission dynamics of these threats.
- Open Access
- 28 November 2014
- Published by Wiley in European Journal of Immunology
- Vol. 45 (3) , 780-793
Epitope‐specific CD4+, but not CD8+, T‐cell responses induced by recombinant influenza A viruses protect against Mycobacterium tuberculosis infection
Tuberculosis remains a global health problem, in part due to failure of the currently available vaccine, BCG, to protect adults against pulmonary forms of the disease. We explored the impact of pulmonary delivery of recombinant influenza A viruses (rIAVs) on the induction of Mycobacterium tuberculosis (M. tuberculosis)‐specific CD4+ and CD8+ T‐cell responses and the resultant protection against M. tuberculosis infection in C57BL/6 mice. Intranasal infection with rIAVs expressing a CD4+ T‐cell epitope from the Ag85B protein (PR8.p25) or CD8+ T‐cell epitope from the TB10.4 protein (PR8.TB10.4) generated strong T‐cell responses to the M. tuberculosis‐specific epitopes in the lung that persisted long after the rIAVs were cleared. Infection with PR8.p25 conferred protection against subsequent M. tuberculosis challenge in the lung, and this was associated with increased levels of poly‐functional CD4+ T cells at the time of challenge. By contrast, infection with PR8.TB10.4 did not induce protection despite the presence of IFN‐γ‐producing M. tuberculosis‐specific CD8+ T cells in the lung at the time of challenge and during infection. Therefore, the induction of pulmonary M. tuberculosis epitope‐specific CD4+, but not CD8+ T cells, is essential for protection against acute M. tuberculosis infection in the lung.
- 28 November 2014
- Published by Wiley in European Journal of Immunology
- Vol. 45 (3) , 780-793
Open AccessEpitope‐specific CD4+, but not CD8+, T‐cell responses induced by recombinant influenza A viruses protect against Mycobacterium tuberculosis infection
Tuberculosis remains a global health problem, in part due to failure of the currently available vaccine, BCG, to protect adults against pulmonary forms of the disease. We explored the impact of pulmonary delivery of recombinant influenza A viruses (rIAVs) on the induction of Mycobacterium tuberculosis (M. tuberculosis)‐specific CD4+ and CD8+ T‐cell responses and the resultant protection against M. tuberculosis infection in C57BL/6 mice. Intranasal infection with rIAVs expressing a CD4+ T‐cell epitope from the Ag85B protein (PR8.p25) or CD8+ T‐cell epitope from the TB10.4 protein (PR8.TB10.4) generated strong T‐cell responses to the M. tuberculosis‐specific epitopes in the lung that persisted long after the rIAVs were cleared. Infection with PR8.p25 conferred protection against subsequent M. tuberculosis challenge in the lung, and this was associated with increased levels of poly‐functional CD4+ T cells at the time of challenge. By contrast, infection with PR8.TB10.4 did not induce protection despite the presence of IFN‐γ‐producing M. tuberculosis‐specific CD8+ T cells in the lung at the time of challenge and during infection. Therefore, the induction of pulmonary M. tuberculosis epitope‐specific CD4+, but not CD8+ T cells, is essential for protection against acute M. tuberculosis infection in the lung.